Clinical Trials
Numerous clinical trials evaluate nicotinamide riboside across Phase 1 through Phase 4 protocols for a wide spectrum of metabolic, vascular, and neurodegenerative conditions, including Parkinson's disease, peripheral artery disease, hypertension, obesity, and age-related physiological decline. Sponsored by academic medical centers, government agencies like the NIDDK, and private industry, these studies span diverse recruitment statuses from completed and actively recruiting—such as dose-optimization and safety protocols—to active, terminated, or upcoming trials.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07782671 | NOT_YET_RECRUITING | Peripheral Artery Disease (PAD) |
Northwestern University |
2026-12 | PHASE3 |
| NCT07741071 | RECRUITING | Alzheimer Disease (AD) |
Haukeland University Hospital |
2026-08-26 | PHASE2 |
| NCT07579429 | RECRUITING | Clonal Cytopenia of Undetermined Significance; Myelodysplastic Syndrome |
University of Colorado, Denver |
2026-05-20 | PHASE2 |
| NCT06853743 | RECRUITING | Huntington Disease |
Oslo University Hospital |
2025-03-18 | PHASE2 |
| NCT06162013 | RECRUITING | Progressive Supranuclear Palsy; Multiple System Atrophy; Corticobasal Syndrome |
Haukeland University Hospital |
2024-03-05 | PHASE2 |
| NCT07693543 | NOT_YET_RECRUITING | Chronic Kidney Disease |
University of California, San Diego |
2026-10-01 | PHASE2 |
| NCT06032923 | RECRUITING | Systemic Lupus Erythematosus (Sle) |
National Heart, Lung, and Blood Institute (NHLBI) |
2024-03-13 | PHASE1; PHASE2 |
| NCT06208527 | RECRUITING | Frailty; Frail Elderly Syndrome; Frailty Syndrome; Aging |
Haukeland University Hospital |
2025-01 | PHASE2 |
| NCT06587945 | RECRUITING | Retinal Detachment |
Center for Eye Research Australia |
2025-09-19 | PHASE4 |
| NCT07649161 | RECRUITING | Healthy Adult |
Massachusetts General Hospital |
2026-06 | |
| NCT05500170 | RECRUITING | Cognitive Impairment; Sleep Quality |
State University of New York at Buffalo |
2023-04-04 | |
| NCT05740722 | RECRUITING | Multiple Sclerosis; Progressive Multiple Sclerosis |
Haukeland University Hospital |
2023-05-03 | PHASE2 |
| NCT06280482 | RECRUITING | Smooth Muscle Dysfunction Syndrome (SMDS) |
The University of Texas Health Science Center, Houston |
2024-03-06 | PHASE1 |
| NCT07703137 | ENROLLING_BY_INVITATION | Parkinson's Disease |
University of Oklahoma |
2026-08-10 | |
| NCT07344636 | RECRUITING | Health Adult Subjects |
ZHANG Jiaqi |
2026-01-06 | |
| NCT04112641 | ACTIVE_NOT_RECRUITING | Chemotherapy-induced Peripheral Neuropathy |
Donna Hammond, PhD |
2020-02-19 | PHASE2 |
| NCT05483465 | RECRUITING | Aging |
University of Oklahoma |
2023-05-03 | PHASE4 |
| NCT04913805 | RECRUITING | Heart Failure With Preserved Ejection Fraction |
University of Pennsylvania |
2021-10-11 | PHASE2 |
| NCT07563322 | RECRUITING | Pulmonary Hypertension |
Vanderbilt University Medical Center |
2026-04-09 | |
| NCT06044935 | RECRUITING | Overweight; Obesity |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2024-01-08 | |
| NCT06567717 | RECRUITING | Idiopathic Pulmonary Fibrosis |
Cedars-Sinai Medical Center |
2025-11-03 | PHASE2 |
| NCT07073352 | RECRUITING | Adverse Childhood Experiences; Endothelial Dysfunction |
University of Wisconsin, Madison |
2025-03-27 | |
| NCT07284225 | NOT_YET_RECRUITING | Healthy Volunteers |
Eye & ENT Hospital of Fudan University |
2025-12-20 | |
| NCT07475208 | NOT_YET_RECRUITING | Hypertension (HTN) |
ZHANG Jiaqi |
2026-04 | |
| NCT05590468 | ACTIVE_NOT_RECRUITING | Mitochondrial Myopathy |
Ralitza Gavrilova |
2023-05-26 | PHASE2 |
| NCT04562831 | ACTIVE_NOT_RECRUITING | Amyotrophic Lateral Sclerosis |
Haukeland University Hospital |
2020-10-07 | |
| NCT06345443 | ENROLLING_BY_INVITATION | Vascular Stiffness |
Mayo Clinic |
2024-11-25 | |
| NCT05023993 | ACTIVE_NOT_RECRUITING | Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm; Prediabetes |
City of Hope Medical Center |
2022-06-23 | |
| NCT04332341 | RECRUITING | Allogeneic Hematopoietic Cell Transplantation |
Case Comprehensive Cancer Center |
2020-05-19 | EARLY_PHASE1 |
| NCT04040959 | ACTIVE_NOT_RECRUITING | Vascular Diseases; Kidney Disease; Blood Pressure; Oxidative Stress |
University of Colorado, Denver |
2019-11-19 | PHASE2 |
| NCT04614714 | NOT_YET_RECRUITING | Preterm Birth; Inadequate Milk Production |
University of California, Davis |
2026-06-01 | PHASE2; PHASE3 |
| NCT05561738 | TERMINATED | Ulcerative Colitis |
University of Pittsburgh |
2024-02-28 | |
| NCT05194397 | RECRUITING | Lymphoblastic Leukemia; Cancer Survivors; Aplastic Anemia; Myelodysplastic Syndromes; Myeloid Leukemia |
Children's Hospital of Philadelphia |
2023-02-23 | PHASE2 |
| NCT06971224 | RECRUITING | Sleep |
Haukeland University Hospital |
2025-10-13 | PHASE2 |
| NCT06018467 | ACTIVE_NOT_RECRUITING | Osteopenia, Osteoporosis; Age-related Bone Loss |
Odense University Hospital |
2023-09-06 | PHASE2 |
| NCT04430517 | COMPLETED | Mild Cognitive Impairment; Mild Alzheimer Disease |
Mclean Hospital |
2022-03-02 | EARLY_PHASE1 |
| NCT06950736 | NOT_YET_RECRUITING | Infertility Female |
The First Affiliated Hospital of Zhengzhou University |
2025-05-05 | |
| NCT04691986 | ACTIVE_NOT_RECRUITING | Sarcopenia; Nicotinamide Adenine Dinucleotide Concentration; Muscle Quality and NAD+ Content |
VA Office of Research and Development |
2023-09-01 | |
| NCT06991712 | RECRUITING | Glaucoma |
Christopher Kai Shun Leung |
2025-05-19 | PHASE2 |
| NCT05095571 | RECRUITING | Amyotrophic Lateral Sclerosis |
Haukeland University Hospital |
2021-10-07 | |
| NCT06425042 | RECRUITING | Healthy Aging; Lifestyle-related Condition; Metabolic Diseases |
Finis Terrae University |
2024-03-01 | |
| NCT07024966 | RECRUITING | Oxidative Stress; Physical Activity; Antioxidant Effect |
Fundació Eurecat |
2025-08-01 | |
| NCT06324877 | UNKNOWN | Ataxia Telangiectasia |
The University of Queensland |
2024-05-01 | |
| NCT05732051 | RECRUITING | Breast Cancer; Metastatic Breast Cancer; Cancer Therapy-Related Cardiac Dysfunction; Cardiotoxicity; Heart Failure |
University Hospital, Akershus |
2023-03-16 | PHASE2 |
| NCT06521307 | UNKNOWN | Acute Kidney Injury; Cardiac Valve Disease |
Instituto Nacional de Cardiologia Ignacio Chavez |
2024-07-24 | |
| NCT05546567 | ACTIVE_NOT_RECRUITING | Safety Issues |
Haukeland University Hospital |
2022-09-28 | |
| NCT03568968 | COMPLETED | Parkinson Disease |
Haukeland University Hospital |
2020-05-06 | PHASE3 |
| NCT05617508 | COMPLETED | Alzheimer Disease; Dementia |
Haukeland University Hospital |
2022-11-22 | PHASE2 |
| NCT03821623 | RECRUITING | Hypertension; Aging |
Douglas Seals |
2019-05-10 | PHASE2 |
| NCT06919328 | RECRUITING | Healthy Aging |
Nutraceuticals Research Institute |
2024-10-31 | |
| NCT05243290 | RECRUITING | Gulf War Illness |
Roskamp Institute Inc. |
2022-04-13 | |
| NCT05589766 | COMPLETED | Parkinson Disease |
Haukeland University Hospital |
2023-01-23 | PHASE2 |
| NCT06214468 | COMPLETED | Drug Toxicity |
University of South Alabama |
2024-01-15 | PHASE1 |
| NCT04192136 | COMPLETED | Friedreich Ataxia 1 |
Children's Hospital of Philadelphia |
2020-09-03 | |
| NCT06005350 | UNKNOWN | NAD |
Charite University, Berlin, Germany |
2023-11-01 | |
| NCT04528004 | ACTIVE_NOT_RECRUITING | Heart Failure, Systolic; Heart Failure NYHA Class IV; Metabolic Disturbance |
University of Washington |
2020-09-26 | EARLY_PHASE1 |
| NCT03818802 | COMPLETED | Healthy Elderly Volunteers |
Mayo Clinic |
2019-09-16 | |
| NCT05703074 | COMPLETED | Long COVID |
University Hospital, Akershus |
2023-01-30 | PHASE2 |
| NCT06534944 | COMPLETED | Peripheral Artery Disease |
University of Oklahoma |
2023-02-27 | PHASE1; PHASE2 |
| NCT04342975 | COMPLETED | AKI |
Mayo Clinic |
2020-12-01 | PHASE2 |
| NCT06382688 | UNKNOWN | Healthy Aging |
Nutraceuticals Research Institute |
2023-11-13 | |
| NCT05698771 | COMPLETED | Healthy |
Haukeland University Hospital |
2022-09-17 | PHASE1 |
| NCT04994561 | WITHDRAWN | Aging |
Vitality in Aging Research Group, Inc. |
2022-06 | PHASE1 |
| NCT04809974 | COMPLETED | Covid19; Sequelae of; Infection; Cognitive Symptom |
Massachusetts General Hospital |
2021-08-28 | PHASE4 |
| NCT04112043 | COMPLETED | Hypertension |
University of Florida |
2020-07-28 | PHASE1 |
| NCT03743636 | COMPLETED | Peripheral Artery Disease |
Northwestern University |
2018-10-01 | PHASE3 |
| NCT03912220 | COMPLETED | Small Fiber Neuropathy |
Johns Hopkins University |
2020-09-01 | PHASE2 |
| NCT03432871 | COMPLETED | Mitochondrial Diseases; Mitochondrial Myopathies; Progressive External Ophthalmoplegia; Progressive Ophthalmoplegia; Progressive; Ophthalmoplegia, External; Mitochondria DNA Deletion; MELAS |
Cambridge University Hospitals NHS Foundation Trust |
2017-12-08 | |
| NCT05593939 | COMPLETED | Aging |
University of Copenhagen |
2022-05-01 | PHASE2 |
| NCT04271735 | COMPLETED | Psoriasis; Atherosclerotic Cardiovascular Disease; Obesity; Dyslipidemia; Cardiometabolic Diseases |
National Heart, Lung, and Blood Institute (NHLBI) |
2020-08-26 | |
| NCT04110028 | COMPLETED | Inflammation; Acute Illness |
Oslo University Hospital |
2019-10-01 | PHASE1; PHASE2 |
| NCT05517122 | COMPLETED | Healthy |
Société des Produits Nestlé (SPN) |
2022-07-12 | |
| NCT03151707 | TERMINATED | Healthy |
Mclean Hospital |
2017-10-01 | PHASE4 |
| NCT04078178 | COMPLETED | Cognition Disorders in Old Age; Mild Cognitive Impairment; Cognitive Decline |
Steven E Arnold, MD |
2020-10-30 | |
| NCT04990869 | COMPLETED | COPD |
University of Copenhagen |
2021-08-05 | |
| NCT02721537 | COMPLETED | Concussion, Mild |
Mayo Clinic |
2016-09 | |
| NCT05344404 | COMPLETED | Parkinson Disease |
Haukeland University Hospital |
2022-04-29 | |
| NCT03685253 | TERMINATED | Diabetic Neuropathy Peripheral |
University of Maryland, Baltimore |
2019-01-24 | PHASE1; PHASE2 |
| NCT04818216 | COMPLETED | SARS-CoV-2 Infection; Acute Kidney Injury |
The University of Texas Health Science Center at San Antonio |
2021-06-11 | PHASE2 |
| NCT03642990 | TERMINATED | Chemotherapy-induced Peripheral Neuropathy; Breast Cancer Metastatic; Platinum-resistant Recurrent Ovarian Cancer; Head and Neck Cancer Stage IV; Endometrial Cancer Stage IV |
Donna Hammond, PhD |
2019-11-08 | PHASE2 |
| NCT04841499 | COMPLETED | Menopause |
University of South Alabama |
2021-04-05 | |
| NCT04407390 | WITHDRAWN | COVID |
University of Copenhagen |
2020-06-01 | PHASE2 |
| NCT03579693 | COMPLETED | Chronic Kidney Disease; Sarcopenia; Frailty |
University of Washington |
2018-11-14 | PHASE2 |
| NCT03635411 | UNKNOWN | Recovery of Function |
Elysium Health |
2018-12-06 | PHASE1 |
| NCT03754842 | COMPLETED | Muscle Injury |
University of Aarhus |
2019-02-12 | |
| NCT03816020 | COMPLETED | Parkinson Disease; Neurodegenerative Diseases |
Haukeland University Hospital |
2019-03-09 | |
| NCT03501433 | COMPLETED | Aging; Lipemia |
Iowa State University |
2018-02-01 | |
| NCT03962114 | COMPLETED | Ataxia Telangiectasia; ATM Gene Mutation |
Radboud University Medical Center |
2019-03-18 | PHASE2 |
| NCT03565328 | TERMINATED | Heart Failure |
National Heart, Lung, and Blood Institute (NHLBI) |
2018-09-27 | PHASE2 |
| NCT03789175 | COMPLETED | Cancer; Skin Fibroblasts; Muscle Weakness |
National Heart, Lung, and Blood Institute (NHLBI) |
2019-03-25 | PHASE1; PHASE2 |
| NCT02942888 | COMPLETED | Mild Cognitive Impairment; NAD |
The University of Texas Health Science Center at San Antonio |
2017-11-30 | |
| NCT03562468 | COMPLETED | Cognitive Function; Mood; Sleep |
ChromaDex, Inc. |
2018-06-13 | |
| NCT03423342 | COMPLETED | Heart Failure, Systolic |
University of Washington |
2016-05-19 | PHASE1; PHASE2 |
| NCT02835664 | COMPLETED | Obesity; Insulin Resistance |
Maastricht University Medical Center |
2016-12 | |
| NCT03727646 | COMPLETED | Heart Failure，Congestive; Heart Failure New York Heart Association Class IV; Mitochondrial Alteration |
University of Washington |
2018-09-26 | EARLY_PHASE1 |
| NCT03176628 | COMPLETED | Acute Kidney Injury |
Massachusetts General Hospital |
2017-11-01 | |
| NCT02950441 | UNKNOWN | Aging |
University of Birmingham |
2016-06 | PHASE2 |
| NCT02812238 | COMPLETED | Atherosclerosis; Diabetes; Coronary Artery Disease |
National Heart, Lung, and Blood Institute (NHLBI) |
2016-06-23 | |
| NCT02303483 | COMPLETED | Obese |
Aarhus University Hospital |
2016-01-04 | |
| NCT02712593 | COMPLETED | Bioavailability |
KGK Science Inc. |
2016-03-21 | PHASE2 |
| NCT02921659 | COMPLETED | Aging |
University of Colorado, Boulder |
2015-04 | PHASE1; PHASE2 |
| NCT02689882 | COMPLETED | Metabolic Disturbance |
University of Washington |
2015-11 | PHASE1 |
| NCT02300740 | COMPLETED | Healthy Participants |
Aarhus University Hospital |
2014-12 | EARLY_PHASE1 |
(data from https://clinicaltrials.gov, updated on 2026-08-24)
Check the
Nicotinamide riboside
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Jump to
Note: Technical data last updated: Sep 1, 2026.